Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H5 mRNA vaccine in healthy adults
NCT06907511Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pandemic flu H5 HA mRNA SD2 vaccine in Avian influenza, sponsored by Sanofi. Started Apr 2025; status: active, not recruiting.
02
Drugs
pandemic flu H5 HA mRNA SD2 vaccine
03
Conditions
Avian influenza
Beyond the preview
Go deeper on NCT06907511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907511.